La catena delle opzioni mostra i dati chiave delle opzioni azionarie di P10 a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per P10..

P10 (NYSE:PX) Azioni, Catena delle Opzioni

P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

P10 Inc

PEXA GROUP LTD by PEXA GROUP LTD

LOCATION SCIENCES GRP NEW by Location Sciences Group PLC

Sorted Group Holdings PLC

PT BANK PERMATA ORD A by PT Bank Permata TBK

PHOENIX COPPER LTD by Phoenix Copper Limited

Phoenix Copper Ltd

PHOENIX COPPER LTD S/ADR by Phoenix Copper Limited

Pioneer Natural Resources Co Com

Pixie Dust Technologies Inc

Invesco Energy Exploration & Production ETF

Invesco FTSE RAFI Developed Markets ex-U.S. ETF

PHOENIX FOOTWEAR GROUP by Phoenix Footwear Group, Inc.

Phoenix Footwear Group Inc

PAX GLOBAL TECHNOLOGY LTD by Pax Global Technology Ltd

Pax Global Technology Ltd

Invesco FTSE RAFI Emerging Markets ETF

PHONEX HOLDINGS INC by PhoneX Holdings, Inc.

PhoneX Holdings Inc

Invesco Dorsey Wright Energy Momentum ETF

Invesco Oil & Gas Services ETF

Pixelworks Inc

Paxman AB

PaxMedica Inc

PHILEX MINING CORP ORD by Philex Mining Corp.

Philex Mining Corp

Pixium Vision SA

Pronexus Inc

Phoenix Plus Corp

PXP Energy Corp

Pexip Holding ASA

Phoenix Apps Inc

PIXARBIO CORPORATION by PixarBio Corporation

Pyxis Tankers Inc

Pyxis Tankers Inc 7.75% PRF PERPETUAL USD 25 - Ser A

PHOENIX MEDIA INV NEW by PHOENIX MEDIA INVT (HOLDINGS) LTD.

Phoenix Media Investment (Holdings) Ltd

PHOENIX VEGA MEZZ LTD by PHOENIX VEGA MEZZ LTD

Poxel SA

PolarX Ltd

Praxsyn Corp

<p>Barclays  analyst Benjamin Budish   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $15 to $16.</p>


News

Price Target

Analyst Ratings

Barclays Maintains Overweight on P10, Raises Price Target to $16

<h3>Gainers</h3>
<ul>
<li><strong>XChange Tec</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) shares moved upwards by 25.7% to $1.42 during Monday's pre-market session. The market value of their outstanding shares is at $159.9 million. </li>
<li><strong>Palmer Square Capital BDC</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NYSE">PSBD</a>) shares moved upwards by 12.24% to $17.0. The market value of their outstanding shares is at $555.1 million. </li>
<li><strong>DigiAsia</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAAS#NASDAQ">FAAS</a>) stock moved upwards by 11.81% to $1.23. The company's market cap stands at $74.6 million. </li>
<li><strong>Mill City Ventures III</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>) shares increased by 11.14% to $3.59. The market value of their outstanding shares is at $22.9 million. </li>
<li><strong>P10</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) shares rose 10.07% to $13.99. The company's market cap stands at $1.5 billion. </li>
<li><strong>Greenpro Capital</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRNQ#NASDAQ">GRNQ</a>) shares rose 10.05% to $2.08. The company's market cap stands at $15.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Guild Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) stock declined by 17.2% to $10.3 during Monday's pre-market session. The company's market cap stands at $637.4 million. </li>
<li><strong>RenaissanceRe Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNR#NYSE">RNR</a>) shares declined by 11.29% to $221.83. The market value of their outstanding shares is at $11.5 billion. </li>
<li><strong>Mercury General</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) shares decreased by 9.53% to $44.0. The market value of their outstanding shares is at $2.4 billion. </li>
<li><strong>Vinci Partners Inv</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) shares declined by 8.5% to $8.51. The market value of their outstanding shares is at $549.9 million. </li>
<li><strong>Heritage Commerce</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTBK#NASDAQ">HTBK</a>) stock fell 8.46% to $8.01. The market value of their outstanding shares is at $490.9 million. </li>
<li><strong>FB Bancorp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLA#NASDAQ">FBLA</a>) stock fell 7.61% to $10.2. The company's market cap stands at $202.3 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-financial-services-stocks/" title="www.benzinga.com/money/best-financial-services-stocks/">www.benzinga.com/money/best-financial-services-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

FAAS

FBLA

GHLD

GRNQ

HTBK

MCVT

PSBD

VINP

12 Financials Stocks Moving In Monday's Pre-Market Session

<p>In the latest quarter, 10 analysts provided ratings for P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated P10 and provided 12-month price targets. The average target is $14.4, accompanied by a high estimate of $21.00 and a low estimate of $12.00. Surpassing the previous average price target of $12.60, the current average has increased by 14.29%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1736251236_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of P10 among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$13.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to P10. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of P10 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of P10's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of P10's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on P10 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering P10: A Closer Look</h2>
<p>P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.</p>
<h3>A Deep Dive into P10's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> P10's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>25.96%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> P10's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>1.89%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> P10's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.4%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> P10's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.17%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> P10's debt-to-equity ratio is below the industry average. With a ratio of <b>0.96</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 10 Analyst Ratings Have To Say About P10

<p>JP Morgan  analyst Kenneth Worthington   upgrades P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) from Neutral to Overweight and raises the price target from $14 to $15.</p>


Upgrades

JP Morgan Upgrades P10 to Overweight, Raises Price Target to $15

<p>Analysts' ratings for P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) over the last quarter vary from bullish to bearish, as provided by 10 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $14.1, along with a high estimate of $21.00 and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 14.63% from the previous average price target of $12.30.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734026509_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of P10 among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$13.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to P10. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of P10 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of P10's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of P10's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on P10 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About P10</h2>
<p>P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.</p>
<h3>Unraveling the Financial Story of P10</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> P10's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>25.96%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>1.89%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> P10's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>0.4%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> P10's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.17%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> P10's debt-to-equity ratio is below the industry average. With a ratio of <b>0.96</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Scoreboard: 10 Ratings For P10

<p>Oppenheimer  analyst Chris Kotowski   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Outperform and raises the price target from $17 to $21.</p>


Oppenheimer Maintains Outperform on P10, Raises Price Target to $21

<p>Barclays  analyst Benjamin Budish   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $14 to $15.</p>


Barclays Maintains Overweight on P10, Raises Price Target to $15

<p>JP Morgan  analyst Kenneth Worthington   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Neutral and raises the price target from $11 to $14.</p>


JP Morgan Maintains Neutral on P10, Raises Price Target to $14

<p>In the latest quarter, 9 analysts provided ratings for P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.39, a high estimate of $16.00, and a low estimate of $10.00. Surpassing the previous average price target of $11.11, the current average has increased by 11.52%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731344410_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive P10 is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$13.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$10.50</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to P10. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of P10 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of P10's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on P10 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind P10</h2>
<p>P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.</p>
<h3>Financial Milestones: P10's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> P10 displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>13.77%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> P10's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>9.84%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> P10's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.95%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> P10's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.84%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.9</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 9 Analyst Insights On P10

<p>Stephens &amp; Co.  analyst John Campbell   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $12 to $13.</p>


Stephens & Co. Maintains Overweight on P10, Raises Price Target to $13

<p>Morgan Stanley  analyst Michael Cyprys   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Equal-Weight and raises the price target from $12 to $13.</p>


Morgan Stanley Maintains Equal-Weight on P10, Raises Price Target to $13

<p>Keefe, Bruyette &amp; Woods  analyst Kyle Voigt   reiterates P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Market Perform and raises the price target from $12.5 to $13.</p>


Reiteration

Keefe, Bruyette & Woods Reiterates Market Perform on P10, Raises Price Target to $13

<p>P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.20 by 30 percent.  The company reported quarterly sales of $74.243 million which beat the analyst consensus estimate of $66.972 million by 10.86 percent.  This is a 25.96 percent increase over sales of $58.942 million the same period last year.</p>


Earnings

Earnings Beats

P10 Q3 2024 Adj. EPS $0.26 Beats $0.20 Estimate, Sales $74.243M Beat $66.972M Estimate

<p>UBS  analyst Adam Beatty   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Neutral and raises the price target from $10.5 to $12.</p>


UBS Maintains Neutral on P10, Raises Price Target to $12

<p>Oppenheimer  analyst Chris Kotowski   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Outperform and raises the price target from $13 to $16.</p>


Oppenheimer Maintains Outperform on P10, Raises Price Target to $16

<p>Morgan Stanley  analyst Michael Cyprys   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Equal-Weight and raises the price target from $10 to $12.</p>


Morgan Stanley Maintains Equal-Weight on P10, Raises Price Target to $12

<p>7 analysts have shared their evaluations of P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for P10, revealing an average target of $10.86, a high estimate of $12.00, and a low estimate of $9.50. This upward trend is apparent, with the current average reflecting a 10.14% increase from the previous average price target of $9.86.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728334843_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive P10. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Ken Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$9.50</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to P10. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of P10 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for P10's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into P10's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on P10 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into P10's Background</h2>
<p>P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.</p>
<h3>A Deep Dive into P10's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> P10's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>13.77%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> P10's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>9.84%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.95%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> P10's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.84%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> P10's debt-to-equity ratio is below the industry average at <strong>0.9</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing P10: Insights From 7 Financial Analysts

<p>Barclays  analyst Benjamin Budish   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $11 to $12.</p>


Barclays Maintains Overweight on P10, Raises Price Target to $12

Enhanced Community Development Awarded $65M In New Markets Tax Credits Program

P10 Announces Agreement To Acquire Qualitas Funds For $63M, Establishing European Presence With $1B In Fee-Paying Assets Under Management And Over 1,300 LPs; Expected To Be Accretive To ANI Per Share In 2025

Michael Cyprys, an analyst from Morgan Stanley, maintained the Hold rating on P10 Holdings (PX – Research Report). The associated price target was ...

P10 Holdings: Steady EPS and Limited Upside Suggest Hold Rating

Morgan Stanley analyst Michael Cyprys raised the firm's price target on P10 (PX) to $13 from $12 and keeps an Equal Weight rating on the shares. Th...

P10 price target raised to $13 from $12 at Morgan Stanley

In a report released today, Chris Kotowski from Oppenheimer maintained a Buy rating on P10 Holdings (PX – Research Report), with a price target of ...

Oppenheimer Sticks to Its Buy Rating for P10 Holdings (PX)

P10 (PX) announced the launch of a new partnership between funds managed by HPS Investment Partners and Enhanced Capital, a P10 affiliated manager,...

P10: HPS Investment Partners, Enhanced Capital launch partnership

P10 (PX) announced the appointment of Mike Goodwin as Chief Information Officer, effective December 2, 2024. Mr. Goodwin will lead the Company's da...

P10 appoints Mike Goodwin as CIO

Barclays analyst Benjamin Budish maintained a Buy rating on P10 Holdings (PX – Research Report) today and set a price target of $15.00. The company...

Barclays Remains a Buy on P10 Holdings (PX)

Chinese EV makers report record deliveries after lower pricing and subsidies boost demand

JPMorgan upgraded P10 (PX) to Overweight from Neutral with a price target of $15, up from $14. The firm made several changes in the brokers, asset ...

P10 upgraded to Overweight from Neutral at JPMorgan

J.P. Morgan favors brokers heading into 2025

The latest announcement is out from P10 Holdings ( ($PX) ). P10, Inc. has appointed Andrew Corsi as the new Chief Accounting Officer, effective Jan...

P10 Holdings Appoints New Chief Accounting Officer

BRDG

CBOE

FRGE

HOOD

LPLA

TSLA

XIACF

XPEV

Press Releases

General

RCP Advisors Secondary and Co-investment Programs Ranked Among Top by PitchBook

P10 Schedules Third Quarter 2024 Earnings Release for Thursday, November 7, 2024

Commodities

HPS Investment Partners and Enhanced Capital Launch Innovative Partnership to Invest in Energy Transition Projects

P10 Reports Third Quarter 2024 Earnings Results

P10 Announces HPS Investment Partners and Enhanced Capital Launch Innovative Partnership to Invest in Energy Transition Projects

P10, Inc. Announces HPS Investment Partners and Enhanced Capital Launch Innovative Partnership to Invest in Energy Transition Projects

Management

P10 Names Mike Goodwin as Chief Information Officer

RCP Advisors Recognized by Pensions & Investments' Best Places to Work in Money Management and Chicago's The Best and Brightest Companies to Work For®

Bonaccord Capital Partners Announces Fund II Final Close at $1.6 Billion

Bonaccord Capital Partners Closes on $1.6 Billion for Fund II

Acadian Asset Management Inc. Common Stock

Acadian Asset Management

AllianceBernstein Holding

Artisan Partners Asset Management Inc. Class A Common Stock

Artisan Partners Asset

Barings BDC

Bain Capital Specialty Finance, Inc. Common Stock

Bain Capital Specialty

Carlyle Secured Lending, Inc. - Closed End Fund

Carlyle Secured Lending

Cohen & Steers

Capital Southwest Corporation - Common Stock

Capital Southwest

DigitalBridge Gr

Federated Hermes

Golub Capital BDC, Inc. - Closed End Fund

Golub Capital BDC

Goldman Sachs BDC

Hercules Capital

Kayne Anderson BDC

MidCap Financial Investment Corporation - Closed End Fund

MidCap Financial

Morgan Stanley Direct Lending Fund Common Stock

Morgan Stanley Direct

New Mountain Finance Corporation - Common Stock

New Mountain Finance

Oaktree Specialty Lending Corporation - Closed End Fund

Oaktree Specialty Lending

Patria Investments Limited - Class A Common Shares

Patria Investments

PennantPark Floating Rate Capital Ltd. Common Stock

PennantPark Floating Rate

Prospect Capital Corporation - Closed End Fund

Prospect Capital

Sixth Street Specialty Lending, Inc. Common Stock

Sixth Street Specialty

Victory Capital Holdings, Inc. - Common Stock

Victory Capital Holdings

Virtus Investment Partners, Inc. Common Stock

Comments

P10

P10 (PX) Opzioni

P10 (NYSE:PX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO